Literature DB >> 10797610

Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month.

A Magalini1, M Puoti, V Putzolu, E Quiros-Roldan, M A Forleo, S Rossi, S Zaltron, A Spinetti, B Zanini, A Zonaro, R Solfrini, G Carosi.   

Abstract

Early monitoring of HCVRNA during interferon treatment may allow clinicians to obtain important information that could help them to adopt therapeutic decisions in individual cases. The hepatitis C virus infection is highly dynamic and a daily high dose of IFN may induce a decline of viremia of 95+/-10% of baseline value after 24 to 48 hours of treatment. The importance of this early antiviral efficacy has not been understood. We have measured HCVRNA levels in 47 patients with chronic hepatitis C infection during interferon treatment to study HCVRNA kinetics and evaluate the predictive value of the early decay of viremia on the virological response after one month of treatment. Sixty percent of treated patients showed early virological response (EVR) and it was significantly associated with low HCVRNA levels and a genotype other than 1b. Finally, the absence of an 85% decline in HCVRNA levels after 3 days of treatment observed in 11 out of 45 patients (24%) was an absolute and very early predictor of the absence of EVR in the study population. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797610      PMCID: PMC6808147          DOI: 10.1002/(sici)1098-2825(2000)14:3<120::aid-jcla6>3.0.co;2-#

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  16 in total

Review 1.  EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver.

Authors: 
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

2.  Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.

Authors:  D R Taylor; S T Shi; P R Romano; G N Barber; M M Lai
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

3.  Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.

Authors:  N P Lam; A U Neumann; D R Gretch; T E Wiley; A S Perelson; T J Layden
Journal:  Hepatology       Date:  1997-07       Impact factor: 17.425

Review 4.  Treatment of chronic viral hepatitis.

Authors:  G M Dusheiko; A J Zuckerman
Journal:  J Antimicrob Chemother       Date:  1993-07       Impact factor: 5.790

Review 5.  Interferon treatment of cirrhotic patients with chronic hepatitis C.

Authors:  R Idilman; N De Maria; A Colantoni; A Dokmeci; D H Van Thiel
Journal:  J Viral Hepat       Date:  1997-03       Impact factor: 3.728

6.  Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C.

Authors:  B Gavier; M A Martínez-González; J I Riezu-Boj; J J Lasarte; N Garcia; M P Civeira; J Prieto
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

Review 7.  Therapy of hepatitis C.

Authors:  M W Fried; J H Hoofnagle
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

Authors:  G L Davis; R Esteban-Mur; V Rustgi; J Hoefs; S C Gordon; C Trepo; M L Shiffman; S Zeuzem; A Craxi; M H Ling; J Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients.

Authors:  H Khorsi; S Castelain; A Wyseur; J Izopet; V Canva; A Rombout; D Capron; J P Capron; F Lunel; L Stuyver; G Duverlie
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

View more
  1 in total

1.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.